Transaction
African Development Bank Group invests USD 15 million in Biologicals and Vaccines Institute's (Biovac) operations in South Africa
- Announced
- 5 August 2026
- Target
- The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited
- Value
- $15m
- Asset class
- Private Credit
- Type
- Debt Financing
- Instrument
- Private Capital (Debt)
- Lead investors
- The African Development Bank Group (AfDB)
- Investors
- The African Development Bank Group (AfDB)
- Sector
- Healthcare / Biotechnology, Pharmaceuticals
- Markets
- Lesotho, Angola, Eswatini, Namibia, Botswana, Mozambique, South Africa
About the target
The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, trading as The Biovac Institute, is a South African biopharmaceutical company based in Pinelands, Cape Town, South Africa. Established in 2003 as a public-private partnership between the South African government and a private consortium, Biovac was created to rebuild South Africa's human vaccine manufacturing capacity following the cessation of vaccine production at the State Vaccine Institute. The company is involved in vaccine development and manufacturing, including upstream and downstream processing, formulation, fill-and-finish manufacturing, labelling and packaging, quality control, distribution and cold-chain logistics. It has entered into technology-transfer partnerships and agreements with international vaccine manufacturers, including Sanofi, Pfizer, EuBiologics, and Biological E. Biovac supplies vaccines in South Africa and other Southern African markets, including Angola, Botswana, Eswatini, Lesotho, Mozambique, and Namibia.
Sources
- empowerafrica.com
- Partner Researchers